Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Affiliations

Varbanova V.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria
Anastasova-Postadzhiyan A.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria
Nedeva A.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria
Nikolov I.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria
Kindekov I.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria
Kuyumdzhieva Y.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria
Petkova N.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria
Vikentieva E.: Laboratory of clinical immunology,, Military Medical Academy – Sofia, Bulgaria
Lubomir M.: Laboratory of Cytogenetics and Molecular Biology, Military Medical Academy – Sofia, Bulgaria
Raynov J.: Clinic of Hematology, Military Medical Academy – Sofia, Bulgaria

Abstract

Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.